for each individual patient remains a significant challenge for general practitioners and psychiatrists. Response and remission are key goals in the management of depression. Acceptability is also an important step towards achieving these goals, since patients require long-term (often life-long) pharmacotherapy (. First-line pharmacotherapy for depressive disorders typically chosen from among the -newer antidepressants‖-either a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) 5 . Escitalopram, the Senantiomer of citalopram, is a selective serotonin reuptake inhibitor (SSRI) antidepressant that is the most selective of the SSRIs 6 . The efficacy of escitalopram has been demonstrated in major depressive disorder (MDD) in both primary care and specialist settings [7] [8] [9] . Amisulpride is a substituted benzamide derivative structurally related to sulpiride. It belongs to the second-generation antipsychotic that preferably binds to dopamine D2/D3 receptors in limbic rather than striatal structures 10 . Amisulpride is indicated for the treatment of acute and chronic schizophrenia with prominent positive and/or negative symptoms due to a dosedependent blockade of dopamine receptors 10, 11 . In addition to antipsychotic effects, preliminary reports suggest that Amisulpride may have antidepressant effects in dysthymia. Amisulpride has been shown to be as effective as comparator in clinical studies in patients with dysthymia and/or major depression 12 . The presumed selectivity of amisulpride for D2 and D3 dopamine receptors has led to the prevailing hypothesis that modulation of dopaminergic signaling is responsible for its antidepressant efficacy. Recent evidence suggests that primary-care providers do not decide on drug treatment or referral for depression on the basis of questionnaire scores alone, and that they consider practical wisdom and clinical judgment to be more important than objective assessments 13, 14 . Assessment of function may, therefore, provide additional, important efficacy information over and above that provided by measuring response and remission. In this regard, emerging data show that escitalopram has an ability to improve functional outcomes in depression patients 15, 16 . Based on the above observations, the present study was conducted to compare efficacy of Amisulpride and Escitalopram by HAM-D and improvement in functional outcomes by Sheehan's Disability Scale (SDS) among depression patients in a tertiary care teaching hospital in Nepal.
MATERIAL AND METHODS:
This study was conducted in the Department of Study Design: The study was an open label study conducted from January 2013 to December 2013. A total of 117 patients diagnosed with depression were randomly divided in two groups: Group I (58 patients) receivedtabletAmisulpride50 mg/day orally and Group II (59 patients) were given tablet Escitalopram 10 mg/day orally. Drug compliance was monitored rigorously, but no drug blood levels were monitored due to lack of any such facility locally. The patients were followed up at 4, 8 and 15 weeks. Adverse drug reactions were monitored at every follow up. Appropriate statistical tools using GraphPadInstat 3.0 were used for analysis. p value < 0.05 was considered significant.
RESULTS:
Out of a total of 117 patients which were included in the study, 18 patients dropped out from the study due to varying reasons: 6 patients were lost to follow up, 6 patients decided to withdraw from the study due to adverse drug reactions, 3 patients were lost due to lack of cost effectiveness, 2 patients requested therapy change and 1 patient was uncooperative. Overall, 99 patients completed the study: 48 patients in Amisulpride group and 51 patients in Escitalopram group. The mean age of the patients in the study drug groups was 46.84±1.10 years. The male: female percentage was 41(41.41%) and 58(58.59%). In our study, 31(31.31%) patients were residing in urban areas and 68(68.69%) patients were residing in rural areas. A total of 47(47.47%) patients were illiterate and 52(52.53%) patients were literate. 65(65.66%) patients were farmers, 23(23.23%) patients were employed and 11(11.11%) belonged to others category (table 1&2) . ISSN: 2250-1177 CODEN (USA): JDDTAO 
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DISCUSSION:
Depressive disorders lead to significant dysfunction, disability and poor quality of life in sufferers and pose a significant burden on the caregivers 17, 18 . In the present study there was a higher prevalence of depression in females which was in accordance with previous studies by Sethi et al and Ramachandran et al depicting that women were more commonly suffering from depression 19, 20 . The greater prevalence of depression among women is not fully understood, although potential contributors include different responses to stressful life events, genetic predisposition and hormonal differences 21 . The mean age group in our study was 46.84±1.10 years which was comparable with previous studies by Dutta et al and Grover et al where incidence of depression was seen predominantly in 30-51 years age group 22, 23 . More depression patients were seen in rural areas as compared to urban areas in the present study. This was comparable with previous studies by Paritala et al, Giel et al and Gautam et al where rural back ground subjects were found to be somatising more than the urban subjects [24] [25] [26] . In our study more number of literates was suffering from depression which was comparable with previous study by Paritala et al and Barsky et al 24, 27 . Farmers were the major sufferers of depression which was in accordance with previous studies by Roberts and Lee 28 which was, based on data from the Epidemiologic Catchment Area (ECA) Program, found ‗farming, fishing and forestry' to have the highest lifetime risk for major depression. Other studies have also shown increased suicide rates among farmers 29, 30 .
A comparative evaluation of Escitalopram and Amisulpride was done in depression patients by measuring improvement in functional outcome using Sheehan's Disability Scale in this 15 week study. Escitalopram is an allosteric selective serotonin reuptake inhibitor (SSRI) with some indication of superior efficacy in the treatment of major depressive disorders. The results of our study revealed highly significant improvement in HAM-D in depressive patients over the study period. Intragroup comparison was made between baseline and 15 weeks in Escitalopram group, highly significant improvement was seen (p<0.0001). This was comparable with previous studies where efficacy of escitalopram has been proven 8, 9, 31 . Amisulpride, a selective D2/D3 receptor second generation antipsychotic is indicated for the treatment of acute and chronic schizophrenia 32 . The presumed selectivity of Amisulpride for D2 and D3 dopamine receptors has led to the prevailing hypothesis that modulation of dopaminergic signaling is responsible for its antidepressant efficacy. In the present study the antidepressant effect of Amisulpride was compared at baseline and at 15 weeks in depressive patients, highly significant improvement was observed (p<0.0001). This was comparable with previous studies by Ravizza L et al and Lecrubier Y et al where antidepressant role of Amisulpride has been proven [33] [34] . Amisulpride has some selectivity for presynaptic dopamine autoreceptors, and exhibits limbic versus striatal selectivity, particularly at low doses, and it has been suggested that this might account for its therapeutic profile 35 .
The improvement in functional impairment was measured by SDS. In the present study highly significant improvement was seen in both Escitalopram and Amisulpride groups. Previous studies by Cipriani et al. and Wade et al, have also shown favorable outcomes in SDS for Escitalopram 36, 15 and study by Smeraldi et al has shown improvement in SDS by Amisulpride, which is comparable to the present study. Proving that patients who take medications that are efficacious and acceptable have a better chance of achieving superior functional improvements compared to those who take agents that are less efficacious and/or not as well accepted 35 . At the end of the study period, intergroup comparison was made between Escitalopram group and Amisulpride group which revealed no significant difference (p<0.05), indicating both the drug were equally efficacious in improving depression and in improving functional outcome.
Safety analysis was done for both the groups and adverse drug reactions were assessed at each follow up. Gastrointestinal disturbances were seen most commonly with both the groups and have been proven in earlier studies 37, 38 . Endocrinological effects like Amenorrhoea and lactation were seen in Amisulpride group and have been seen in previous studies 39 . Other side effects like insomnia, agitation and dryness of mouth were seen similarly in both groups and were comparable with previous studies 40, 41 .
Study Limitations: The study was an open label study. Both doctors and patients were aware of the treatments. Hence there could be chances of bias. Sample size was small and the patients were followed up for only 15 weeks.
CONCLUSION:
Both Escitalopram and Amisulpride were highly effective in improving functional outcome in depression patients. But intergroup comparison revealed no significant difference between the two groups. A double blind study with larger sample size and longer duration of follow up can substantiate the findings of the present study.
ACKNOWLEDGEMENT:
Authors would like to thanks to the administration and Institutional Ethics Committee of Nepalganj Medical college, Nepal for their support in conducting this study. At the same time they can't forget the unconditional support of the staff members of psychiatry department.
